Chidamide and venetoclax synergistically exert cytotoxicity on multiple myeloma by upregulating BIM expression

BACKGROUND: Multiple myeloma (MM) is the second most common hematologic malignancy with almost all patients eventually having relapse or refractory MM (RRMM), thus novel drugs or combination therapies are needed for improved prognosis. Chidamide and venetoclax, which target histone deacetylase and B...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Liqin, Chen, Qingxiao, Gu, Huiyao, Li, Yi, Cao, Wen, Liu, Yang, Qu, Jianwei, Hou, Yifan, Chen, Jing, Zhang, Enfan, He, Jingsong, Cai, Zhen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9264603/
https://www.ncbi.nlm.nih.gov/pubmed/35799216
http://dx.doi.org/10.1186/s13148-022-01306-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9264603/
https://www.ncbi.nlm.nih.gov/pubmed/35799216
http://dx.doi.org/10.1186/s13148-022-01306-7

Ejemplares similares